Phyton Biotech Announces Successful Establishment of Plant Cell Lines to Provide Key Building Block for Treatment of Rare Dermatologic Diseases


FORT WORTH, Texas–()–Phyton Biotech today announced that it has established high yielding plant cell lines of Veratum californicum, the source of cyclopamine, a key raw material for PellePharm’s patedigib topical gel, an investigational treatment for use in rare skin conditions. This is the first step in efforts to enable the renewable production of cyclopamine.

Using proprietary Phyton Plant Cell Fermentation (PCF®) technology, researchers have succeeded in developing high-yielding plant cell lines of V. californicum and established protocols for cryopreservation, allowing stable long-term storage of cell lines in liquid nitrogen. Additionally, Phyton Biotech has demonstrated the ability to express cyclopamine directly from V. californicum plant cell cultures via PCF® and have also shown that cyclopamine can be expressed efficiently in a standard bioreactor environment. Further development and full scale-up to a commercially viable process are planned in the next phase of the project.

“Currently, the raw material for patidegib comes from a wild plant, Veratum californicum, and while we are committed to harvesting the plant sustainably, a plant-based approach is highly desirable,” said Gerd Kochendoerfer, Ph.D., senior vice president and chief operating officer of PellePharm. “We appreciate the technical advancements made by the Phyton team and hope that we will be able to expand and leverage their innovative services as an alternative supplier of this raw material for the potential commercialization of patidegib topical gel. »

PellePharm is currently investigating the safety and efficacy of patidegib topical gel in a Phase 3 study for reducing the burden of basal cell carcinoma in patients with Gorlin syndrome. Additionally, the company is engaged in a phase 2 trial studying it in high frequency basal cell carcinoma (HF-BCC).

In addition to these technical milestones, patent coverage has recently been expanded with the issuance of a patent by the European Patent Office (EPO).

Colin Marr, President of Phyton Biotech comments on this progress:

We are delighted to have reached an important milestone in this project where we have established a proof of concept for the development of cyclopamine through the use of our PCF technology, and that it can be used in the medical treatment of PellePharm. patients with Gorlin syndrome. We look forward to continuing our work with PellePharm, an important Phyton customer, and wish them much success in developing this breakthrough medical treatment.

About Phyton Biotech

Phyton Biotech, a wholly owned subsidiary of DFB Pharmaceuticals, is a global leader in Plant Cell Fermentation (PCF®) technology, providing comprehensive services for the development and commercialization of molecules, extracts and recombinant products at herbal, serving Pharmaceutical, Chinese Traditional Medicine, Cosmetics, Agriculture and Food Ingredient industries. By using PCF®, Phyton Biotech offers a balanced time, risk and cost pathway to commercially viable production processes, overcoming the limitations often encountered with traditional plant extraction and chemical synthesis.

As a biotechnology leader with GMP certified facilities in Germany and Canada, Phyton Biotech has a successful track record in developing and implementing innovative solutions for customers around the world. The company is now the world’s largest producer of paclitaxel and docetaxel via PCF®, with the ability to meet more than a third of global demand for these critical active pharmaceutical ingredients. For more information, please visit

About PellePharm

Founded by world leaders in Hedgehog pathway signaling, PellePharm, a BridgeBio company, is committed to targeting rare forms of basal cell carcinoma, including Gorlin syndrome and high-frequency basal cell carcinoma (HF-BCC ), at their source. PellePharm’s mission is to improve the quality of life for people with Gorlin Syndrome and CBC-HF by providing an easy-to-use topical gel that could potentially reduce the need for regular, painful and disfiguring surgical procedures. Patidegib topical gel is a topical formulation of a proprietary hedgehog inhibitor.

About Patidegib

Patidegib topical gel, an investigational treatment, is designed to reduce basal cell carcinoma (BCC) tumor burden in people with Gorlin syndrome and high-frequency BCC (HF-BCC) by blocking the disease at its source in the hedgehog signaling pathway. Patidegib topical gel has shown great promise in a Phase 2 clinical study for the attenuation of BCC tumors in Gorlin syndrome. The topical formulation of patidegib was developed with the goal of providing the clinical activity previously demonstrated by oral patidegib in Phase 1 trials and a favorable safety profile without the adverse systemic side effects seen with the oral class of hedgehog inhibitors. . The topical gel formulation is stable at room temperature for at least two years, potentially making it an option for the ongoing home management of Gorlin Syndrome and CBC-HF. PellePharm has received both Orphan Drug Designation and Breakthrough Treatment Designation for Patidegib topical gel in Gorlin’s syndrome from the FDA, as well as Orphan Drug Designation in Gorlin’s syndrome from the FDA’s Orphan Drug Committee. EMA in the EU.


Comments are closed.